This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Opko Health Is What the Doctor Ordered

This stock gets a momentum grade and performance grade of A+; there are not many stocks that get an A+ performance or momentum grade right now. This is a rare bird.

That being said, remember that this is a smaller stock. Smaller stocks carry greater risk. For this reason, I'm a big proponent of owning 25 to 35 stocks in your portfolio that fit your risk profile.


Next let's take a look at the valuation of Opko. This is difficult to do right now because the company is still losing money. In fact, Opko is expected to lose 17 cents per share this year.

However, when I look at the company's sales growth over the last four quarters, I see growth in sales up between 73% and 133% from quarter to quarter.

It would be pretty hard to carry on a trajectory like that of sales growth and not eventually crossover the line into profitability. I think that with Opko's products and pipeline it has ample upside potential going forward.

Stock Chart: Lastly, we have to take a look at the stock chart. Opko's chart was dead in the water from March until August but then it started taking off. And it's been taking off ever since.

I bought Opko and I think you can see why as it has the numbers to back it up; it fits my style of investing. Now it is a member of my aggressive growth portfolio. Out of 3,575 stocks, Opko comes in as the number-one-ranked stock in my Best Stocks Now! app.

Are there guarantees in the market? No. But can you do your best to try to put probability on your side? Yes.

At the time of publication the author had no position in any of the stocks mentioned.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
OPK $14.28 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%
TSLA $206.79 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs